12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Bio-T-Gel regulatory update

BioSante said FDA accepted for filing an NDA from partner Teva for Bio-T-Gel to treat hypogonadism....

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >